TAKE PARTIAL PROFITS ON ACORDA $ACOR

TAKE PARTIAL PROFITS ON ACORDA $ACOR

These posts were published on ZYX Short Sell Change Alert.

Consider taking profits on one-half of Acorda (ACOR) in the zone of $20 to $21.05.  Stop on the remaining is $21.55 to $22.36.

 

You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE  30 day trial.

Check out our enviable performance in both bull and bear markets.

FREE: SUBSCRIBE TO ‘GENERATE WEALTH’ NEWSLETTER

Related Posts

TAKE MORE PROFITS ON ACORDA AND EXIT THE POSITION WITH A PLAN TO RE-ENTER $ACOR

This post was just published on ZYX Short Sell Change Alert. On a fundamental basis, the prior target makes sense.  However since Acorda ...

A NEW IDEA ON BIOTECH COMPANY ACORDA ON PATENT INVALIDATION $ACOR $MYL $TEVA

These posts were published on ZYX Short Sell Change Alert. The short zone for Acorda Therapeutics (ACOR) is $24.50 to $26.40.  Since the ...

GREAT PROFITS ON OUR SHORT ON MS WALKING DRUG COMPANY ACORDA, STOCK CRUSHED ON PATENT RULING $ACOR

This post was just published on ZYX Short Sell Change Alert. ACOR is short from $48.73.  The stock was halted at $20.33, down $6.44.  ...

ACORDA THERAPEUTICS (ACOR): TIME TO TAKE PROFITS

It is time to take profits on Acorda Therapeutics (ACOR).   Consider  taking profits on the entire position of Acorda ...

ACORDA THERAPEUTICS (ACOR) AND BIOGEN (BIIB) RUMOR MONGERS OUT IN FORCE

Acorda Therapeutics (ACOR)  rumor spreaders are out in force. They are misleading the uninformed investors about a statement Biogen ...

TAKING PARTIAL PROFITS ON ACORDA THERAPEUTICS (ACOR)

Subscribers to ZYX  Short Sell Change Alert took partial profits on Acorda  Therapeutics (ACOR)at $30.20 on Friday. We are holding ...

ACORDA THERAPEUTICS (ACOR) UP MOVE IS AN OPPORTUNITY

Acorda Therapeutics (ACOR) is up due to the positive opinion on Marketing Authorization Application for its MS drug Ampyra in Europe.  This ...

PROTECTING PROFITS ON ACOR

We are lowering the stop on ACOR to $22.39 to protect profits.

NOW WE ARE SHORT ON ACOR

As per the prior  post, now we are short on ACOR   from $30.98.

WE HAVE BEEN PROVEN RIGHT ON AMPYRA FROM ACORDA THERAPEUTICS

Today Acorda Therapeutics (ACOR) reported earnings. Acorda stock has risen on hopes for blockbuster sales of its MS walking drug ...

EXITING ACOR WITH PROFIT RIGHT HERE AT $32.61.

Our negative thesis on Acordia Therapeutics (ACOR) has not changed.  However we are positive on the group, therefore we will ...

ADDING TO $ACOR (ACORDA THERAPEUTICS) SHORT SALE POSITION HERE AT $38.15

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE ...

AS PER PRIOR POST, ADDING TO $ACOR (ACORDIA) SHORT AT $33.37

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE ...

UPDATE ON OPEN INDIVIDUAL STOCK POSITIONS

We are exiting $BCRX and $AVAV; please see separate posts for the reasons.We are short on $ACOR with average price ...

WOW! FDA AGREES WITH OUR LONGSTANDING ASSESSMENT OF FAMPRIDINE-SR , SHORT SELL $ACOR (ACORDIA) PER OUR PRIOR POST

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE ...

ACOR (ACORDIA) FAMPRIDINE IS NOT A VERY GOOD DRUG EVEN IF IT WORKS AS ADVERTISED

The FDA Peripheral and Central Nervous System Drugs Advisory Committee meets today to review ACOR's Fampridine-SR for improvement of walking ...

Follow

Get every new post delivered to your Inbox

Join other followers